Is a Biopsy Required to Classify Patients with Idiopathic Retroperitoneal Fibrosis as IgG4-RPF or Non-IgG4-RPF?

Abstract

Objective Our aim was to group cases of idiopathic retroperitoneal fibrosis (IRPF) into those associated with immunoglobulin (Ig) G4-related disease (IgG4-RD) (IgG4-RPF) and those not associated with IgG4-RD (non-IgG4-RPF) and to compare the clinical presentation, laboratory findings, imaging, and treatment methods.

Methods A total of 46 patients were included in the study. According to the assessment by two experienced rheumatologists and the IgG4-RPF classification criteria published by the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) in 2019, 11 patients who were admitted as IgG4-RPF were included in the IgG4-RPF group and 35 patients who were not admitted as IgG4-RPF were included in the non-IgG4-RPF group. The clinical and demographic characteristics, affected sites, laboratory results and treatments were retrospectively evaluated and compared.

Results The mean age of our patients was 50.69 (±11.33) in the non-IgG4-RPF group and 55.36 (±7.80) in the IgG4-RPF group and was similar in both groups (p=0.340). The male gender dominated in both groups. Although there was no significant difference between the groups in terms of acute renal failure (p=0.074), this was more frequent in the IgG4-RPF group (81.82%). An increased IgG4 concentration was found in about half (n=6, 54.55%) of the patients in the IgG4-RPF group, while this was present in only 5.71% (n=2) of the patients in the non-IgG4-RPF group (p=0.001). The most commonly used diagnostic imaging modality was computed tomography. Biopsy was performed in almost all patients (n=10, 90.91%) in the IgG4-RPF group and 11 (31.43%) in the non-IgG4-RPF group (p<0.001). Drug treatment alone and drug treatment in combination with interventional treatment were the most commonly used treatment modalities in the non-IgG4-RPF group (n=12, 34.29% for both). In the IgG4-RPF group, the combination of medical and interventional treatment was the most commonly used treatment modality (n=5, 45.45%). No significant difference was found between the two groups in the assessment of treatment success (p>0.05).

Conclusion IRPF can present with similar clinical and imaging findings in IgG4-RPF and non-IgG4-RPF groups. Since a similar treatment success can be achieved in both groups with similar therapeutic agents, we believe that a biopsy is not necessary in patients with an uncertain diagnosis of IRPF.

Keywords

biopsy - computed tomography - idiopathic retroperitoneal fibrosis - immunoglobulin G4-related disease - medical therapy

Schlüsselwörter

biopsie - computer tomographie - idiopathische retroperitoneale fibrose - immunglobulin G4-bedingte erkrankung - medizinische therapie

Publication History

Article published online:
19 June 2024

• References

• 1 Trevisani HA. Peritoneal fibrosis. Rev Nefrol Dial y Traspl 2015; 35: 88-100
• 2 Fenaroli P, Maritati F, Vaglio A. Into Clinical Practice: Diagnosis and Therapy of Retroperitoneal Fibrosis. Curr Rheumatol Rep 2021; 23
• 3 Łoń I, Wieliczko M, Lewandowski J. et al. Retroperitoneal Fibrosis Is Still an Underdiagnosed Entity with Poor Prognosis. Kidney Blood Press Res 2022; 47: 151-162
• 4 Duhan S, Keisham B, Bazigh K. et al. Retroperitoneal Fibrosis: Still a Diagnostic Challenge. Cureus 2023; 15: 5-6
• 5 Vaglio A, Maritati F. Idiopathic retroperitoneal fibrosis. J Am Soc Nephrol 2016; 27: 1880-1889
• 6 Wallace ZS, Naden RP, Chari S. et al. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. Arthritis Rheumatol 2020; 72: 7-19
• 7 Kawano M, Saeki T, Nakashima H. IgG4-related kidney disease and retroperitoneal fibrosis: An update. Mod Rheumatol 2019; 29: 231-239
• 8 Van Bommel EFH, Jansen I, Hendriksz TR. et al. Idiopathic retroperitoneal fibrosis: Prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore) 2009; 88: 193-201
• 9 Jois RN, Gaffney K, Marshall T. et al. Chronic periaortitis. Rheumatology 2004; 43: 1441-1446
• 10 Raglianti V, Rossi GM, Vaglio A. Idiopathic retroperitoneal fibrosis: An update for nephrologists. Nephrol Dial Transplant 2021; 36: 1773-1781
• 11 Gianfreda D, Superchi E, Peyronel F. et al. Chronic periaortitis: A clinical approach. Rev Med Interne 2023; 44: 79-84
• 12 Vaglio A, Palmisano A, Alberici F. et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: An open-label randomised controlled trial. Lancet 2011; 378: 338-346
• 13 Umehara H, Okazaki K, Kawa S. et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 2021; 31: 529-533
• 14 Lanzillotta M, Lanzillotta M, Mancuso G. et al. Advances in the diagnosis and management of IgG4 related disease. BMJ 2020; 369
• 15 Cases ACS. IgG4-Related Disease 2010; 34: 1812-1819
• 16 Wang K, Wang Z, Zeng Q. et al. Clinical characteristics of IgG4-related retroperitoneal fibrosis versus idiopathic retroperitoneal fibrosis. PLoS One 2021; 16: 1-10
• 17 Li J, Wang H, Wang M. et al. Differences of clinicopathological features between IgG4-related and non-IgG4-related idiopathic retroperitoneal fibrosis. Int J Rheum Dis 2022; 25: 440-446 DOI: 10.1111/1756-185X.14287.
• 18 Razok A, Romero Noboa ME, Sami F. et al. IgG4-related disease and isolated retroperitoneal fibrosis: a narrative review. ARP Rheumatol 2023; 2: 155-157
• 19 Rossi GM, Rocco R, Accorsi Buttini E. et al. Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease. Intern Emerg Med 2017; 12: 287-299 DOI: 10.1007/s11739-016-1599-z.
• 20 Kim IY, Eun YH, Jeong H. et al. Clinical characteristics and outcomes of 61 patients with chronic periaortitis including IgG4-related and non-IgG4-related cases. Int J Rheum Dis 2017; 20: 1751-1762 DOI: 10.1111/1756-185X.13194.
• 21 Wallace ZS, Deshpande V, Mattoo H. et al. IgG4-related disease: Clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol 2015; 67: 2466-2475 DOI: 10.1002/art.39205.
• 22 Ebbo M, Daniel L, Pavic M. et al. IgG4-related systemic disease: Features and treatment response in a French cohort: Results of a multicenter registry. Medicine (Baltimore) 2012; 91: 49-56 DOI: 10.1097/MD.0b013e3182433d77.
• 23 Yamada K, Yamamoto M, Saeki T. et al. New clues to the nature of immunoglobulin G4-related disease: A retrospective Japanese multicenter study of baseline clinical features of 334 cases. Arthritis Res Ther 2017; 19: 1-10 DOI: 10.1186/s13075-017-1467-x.
• 24 Maritati F, Rocco R, Buttini EA. et al. Clinical and prognostic significance of serum IgG4 in chronic periaortitis. An analysis of 113 patients. Front Immunol 2019; 10: 1-10 DOI: 10.3389/fimmu.2019.00693.
• 25 Cohan RH, Shampain KL, Francis IR. et al. Imaging appearance of fibrosing diseases of the retroperitoneum: can a definitive diagnosis be made?. Abdom Radiol 2018; 43: 1204-1214 DOI: 10.1007/s00261-017-1282-5.
• 26 Altshuler E. Atypical Presentation of Idiopathic Retroperitoneal Fibrosis Effectively Treated With Colchicine After Lymphoma Misdiagnosis. Cureus 2021; 13: 1-7 DOI: 10.7759/cureus.14756.
• 27 Boyeva V, Alabsi H, Seidman MA. et al. Use of rituximab in idiopathic retroperitoneal fibrosis. BMC Rheumatol 2020; 4: 1-7 DOI: 10.1186/s41927-020-00140-9.
• 28 Adler S, Lodermeyer S, Gaa J. et al. Successful mycophenolate mofetil therapy in nine patients with idiopathic retroperitoneal fibrosis. Rheumatology 2008; 47: 1535-1538 DOI: 10.1093/rheumatology/ken291.
• 29 De Socio G, Verrecchia E, Fonnesu C. et al. Effectiveness of colchicine therapy in 4 cases of retroperitoneal fibrosis associated with autoinflammatory diseases. J Rheumatol 2010; 37: 1971-1972 DOI: 10.3899/jrheum.100352.
• 30 Zen Y, Onodera M. et al. Retroperitoneal Fibrosis: A Clinicopathologic Study With. Ratio 2009; 33: 1833-1839